MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma
Mohan S, Vander Broek R, Shah S, Eytan D, Pierce M, Carlson S, Coupar J, Zhang J, Cheng H, Chen Z, Van Waes C. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 3946-3956. PMID: 25977343, PMCID: PMC4558307, DOI: 10.1158/1078-0432.ccr-14-3377.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBenzamidesCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell SurvivalCell Transformation, NeoplasticCytokinesDiphenylamineDisease Models, AnimalDrug Resistance, NeoplasmDrug SynergismGene ExpressionGenes, ReporterHead and Neck NeoplasmsHumansInflammation MediatorsMitogen-Activated Protein Kinase KinasesMorpholinesNF-kappa BPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Kinase InhibitorsSignal TransductionSquamous Cell Carcinoma of Head and NeckTOR Serine-Threonine KinasesTranscription Factor AP-1Transcriptional ActivationTriazinesXenograft Model Antitumor Assays